{{Rsnum
|rsid=2077102
|Gene=BAT3
|Chromosome=6
|position=31644063
|Orientation=minus
|GMAF=0.1556
|Gene_s=BAG6
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 70.8 | 25.7 | 3.5
| HCB | 66.4 | 32.1 | 1.5
| JPT | 58.0 | 33.9 | 8.0
| YRI | 93.9 | 6.1 | 0.0
| ASW | 73.7 | 24.6 | 1.8
| CHB | 66.4 | 32.1 | 1.5
| CHD | 77.1 | 18.3 | 4.6
| GIH | 81.2 | 16.8 | 2.0
| LWK | 90.0 | 9.1 | 0.9
| MEX | 75.9 | 22.4 | 1.7
| MKK | 82.1 | 16.7 | 1.3
| TSI | 80.4 | 19.6 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2077102
|Name_s=intron 12 c.1560+19G>T, c.1578+19G>T
|Gene_s=BAT3
|Feature=
|Evidence=PubMed ID:19837266
|Annotation=Risk or phenotype-associated allele, tested allele: unspecified; multiethnic minor allele is T per dbSNP Phenotype: In 114 cases and 414 controls (n = 528), univariate analysis of disease association showed OR = 0.52 for heterozygote, OR = 0.77 for homozygous, versus homozygous wild type, in ALL, with P(trend) OR = 0.62, p = 0.04 using an additive model. Study size: 528. Study population/ethnicity: Childhood acute lymphoblastic leukemia (<=14 years) and healthy newborn controls (1988 to 1999) from South Wales in the United Kingdom. Significance metric(s): p = 0.04. Type of association: CO.
|Drugs=
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA165110228
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2077102
|overall_frequency_n=1202
|overall_frequency_d=10758
|overall_frequency=0.111731
|n_genomes=8
|n_genomes_annotated=0
|n_haplomes=8
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}